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extremity DVT [5]. The type of the central venous catheter
inﬂuences the rate of thrombotic complication [6]. Infections of
central venous catheters increase the risk of catheter-related
thrombosis in patients with malignancy [7]. Prophylaxis of
venous thromboembolism with heparin, low-molecular-weight
heparin or low-dose warfarin may reduce the incidence of
catheter-related thrombosis, which is however, not yet a
standard procedure, as discussed by the authors [8].
These risk factors and the prophylactic measures have not
been documented in the study and may substantially inﬂuence
the reported data. Thus, the data does not support the con-
clusion that central venous line alone is, a very strong risk factor
for arm vein thrombosis. The present data only indicate an
increased risk for upper extremity DVT by the combination of
central venous line and chemotherapy. Additional information
on the type of central venous catheter, concomitant infection,
the type of the central venous line and the use of anticoagulants
in or out of hospital would deﬁne precisely the risk factors for
upper extremity DVT and the outcome of the patients.
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In their comment, Harenberg andMannheim [1] postulate that
our large population-based case–control study on risk factors
for upper extremity deep venous thrombosis (UE-DVT) [2]
only indicates an increased risk for the combination of a central
venous catheter (CVC) and chemotherapy and that informa-
tion on additional parameters, such as type of CVC, concom-
itant infection, or anticoagulant prophylaxis, is needed to
deﬁne precisely the risk factors for UE-DVT for patients with a
CVC. Indeed, the risk of UE-DVT in a patient with a CVC is
the result of the interaction between numerous patient-related
factors, acquired as well as genetic risk factors, including CVC-
related factors. In this Journal, a review of risk factors for CVC-
related thrombosis is given by van Rooden et al. [3].
In our study, patients with a CVC (mostly cancer patients
who received intensive chemotherapy) had a highly increased
risk of UE-DVT (ORadj 1136, 95% CI: 153–8448) compared
with patients who had not used a CVC, in whom UE-DVT is
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rare. For patients with a CVC without cancer, the odds ratio
was, however, also high, indicating a more than 250-fold
increased risk compared with those without a CVC (ORadj 262
95% CI: 30–2288), which shows the thrombogenicity of these
devices. Certainly, chemotherapy could induce a systemic
hypercoagulable state, which may increase the risk of CVC-
related thrombosis. However, chemotherapeutic agents and
other medication are delivered into the bloodstream at the level
of the superior caval vein/right atrium, whereas CVC-related
thrombosis in the majority of cases is located at a more
proximal level than the superior caval vein/right atrium [3].
Another argument in favor of the CVC itself as the major
trigger comes from a large observational study in patients with
CVC-related thrombosis receiving intensive chemotherapy,
where the contra-lateral vein segments, regularly inspected by
ultrasound, were usually free of thrombosis [4]. Analogously to
our ﬁndings, it has been demonstrated that patients with
pacemaker leads, who are free of cancer and prothrombotic
medication, also have an increased risk of thrombosis [5].
Pathophysiologically, a plausible explanation is that the
presence of a CVC, as a non-biological surface in the
bloodstream, activates the coagulation pathway, or induces
endothelial trauma caused by the indwelling CVC or insertion
procedures, or both [3]. Other risk factors may additionally
contribute to the occurrence of thrombosis, such as concom-
itant infection or a prothombotic state because of thrombo-
philia, malignancies, or certain drugs.
The need for anticoagulant prophylaxis for CVC-related
thrombosis is still debatable. Despite initial recommendations
in 2001 [6], anticoagulant prophylaxis was given to only 10–
20%of theDutchOncology andHaematologyDepartments in
patients who received a CVC for intensive chemotherapy [7].
The latest guidelines of the ACCP (2004) do not recommend
anticoagulant prophylaxis [8]. Recently, in several large trials,
no beneﬁcial effect was obtained from anticoagulant prophyl-
axis [9–11] in patients with a CVC.We therefore do not believe
that these changes in the policy on anticoagulant prophylaxis
have inﬂuenced our estimates.
Central venous catheter-related characteristics, such as type
of catheter, concomitant infections, and therapy administered
through the catheter or anticoagulant prophylaxis, were not
recorded in our study, as this was not the primary goal. In our
study, patients with UE-DVT were analyzed for various risk
factors of DVT. Patients had been treated in a large number of
hospitals in thewestern part of theNetherlands,which therefore
most likely represents various CVC-related policies. In conclu-
sion, we believe that our study gives a representative overall
risk-estimation for the group of patients with a UE-DVT in
general, including the substantial effect caused by CVC.
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